FDA rejects Spectrum’s bladder cancer med, may retool study

The FDA has sent a complete response letter to the biotech

Spectrum has said in a SEC filing that the U.S. regulator rejected its application for Qapzola (apaziquone) in bladder cancer.

This comes after the FDA issued a complete response letter to the small cap biotech this week for its NDA.

In a brief update, the company’s SEC filing said: “On November 17, 2016, Spectrum Pharmaceuticals, Inc. (the “Company”) received a Complete Response Letter from the U.S. Food and Drug Administration (the “FDA”) with respect to the Company’s New Drug Application for QAPZOLA™ (apaziquone for intravesical instillation).

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“On November 15, 2016, the Company met with the FDA to discuss the strategy for further development of QAPZOLA.”

It said that, based on its talks with the FDA, it was now “evaluating a new smaller study that would replace the ongoing Phase III program in which enrollment has been stopped. “

Further details about the FDA’s concerns that lead to its rejection have not been given. 

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.